October 2022 in “European Heart Journal” Potent extracellular vesicles from cardiosphere-derived cells can improve heart health and other functions in aging.
30 citations
,
June 2014 in “Seminars in Immunology” Future research on ectodysplasin should explore its role in diseases, stem cells, and evolution, and continue developing treatments for genetic disorders like hypohidrotic ectodermal dysplasia.
61 citations
,
April 2023 in “Advanced Materials” The new electrode improves long-term monitoring on hairy skin by reducing motion issues and is easy to use.
25 citations
,
July 2022 in “Pharmaceutics” Spanlastic nanovesicles can improve efinaconazole delivery through nails.
1 citations
,
July 2024 in “Nanomedicine” Stem cell-derived vesicles improve blood vessel growth in limbs.
45 citations
,
October 2018 in “JCI Insight” Entospletinib effectively prevents eye and skin GVHD in mice.
15 citations
,
April 2016 in “Medicine” SLE patients with Evans syndrome often show blood issues and need careful monitoring and treatment.
12 citations
,
February 2025 in “Scientific Reports” MSC-EVs and UCB-EVs improve skin wound healing and reduce scarring.
July 2021 in “British Journal of Dermatology” Laser treatment for skin conditions VEN and ILVEN is effective and liked by patients.
7 citations
,
May 2025 in “Stem Cell Research & Therapy” Standardized methods are needed to understand how process conditions affect extracellular vesicle protein content for skin therapy.
3 citations
,
April 2021 in “Biomolecules & Therapeutics” The protein ER71/ETV2 helps regrow hair after chemotherapy by improving the growth of new blood vessels.
222 citations
,
January 2003 in “Critical Reviews in Therapeutic Drug Carrier Systems” Ethosomes can safely and effectively deliver various drugs deep into the skin.
15 citations
,
June 2025 in “Journal of Extracellular Vesicles” Standardized guidelines are needed to improve drug-loaded extracellular vesicle purification.
9 citations
,
August 2021 in “Biomedicines” 17β-estradiol boosts APE1/Ref-1 secretion in cells and mice via a calcium-dependent pathway.
14 citations
,
April 2020 in “Journal of the American Academy of Dermatology” Viral reactivation is rare at the time of DRESS diagnosis in the U.S.
45 citations
,
July 2025 in “Journal of Medicinal Chemistry” The document discusses the submission of a New Drug Application (NDA) to the U.S. FDA for vepdegestrant (ARV-471), a PROTAC protein degrader targeting the estrogen receptor, by Arvinas and Pfizer. This submission is based on positive results from the Phase 3 VERITAC-2 trial and marks a significant milestone as vepdegestrant is anticipated to be the first FDA-approved PROTAC degrader. PROTACs, a novel class of molecules, selectively degrade disease-causing proteins and offer advantages over traditional small molecule inhibitors, such as mitigating off-target effects and overcoming drug resistance. Despite concerns about their large molecular weight and drug-like properties, recent clinical results have been promising. The success of PROTACs has inspired the development of other chimeric molecules for therapeutic applications.
March 2026 in “Journal of the European Academy of Dermatology and Venereology” Exosomes show promise in dermatology but need more research and FDA approval for clinical use.
17 citations
,
January 2025 in “Journal of Nanobiotechnology” Bacterial extracellular vesicles could revolutionize regenerative medicine but need safety improvements.
March 2026 in “Pharmaceutics” TheDES improve drug delivery through the skin but need more safety checks.
May 2026 in “Frontiers in Immunology” Extracellular vesicles (EVs) play a dual role in atopic dermatitis (AD) by contributing to both its pathogenesis and potential treatment. Pathogen-derived EVs, such as those from Staphylococcus aureus, disrupt the skin barrier and promote inflammation, while therapeutic EVs from sources like mesenchymal stem cells show promise in restoring barrier function and modulating the immune response. Despite their potential, challenges such as standardization, mechanistic understanding, and safety data remain. Future research should focus on overcoming these challenges to harness EVs for precision diagnostics and therapies in AD.
Tiny particles called extracellular vesicles show potential for improving skin health in cosmetics, but more research is needed to confirm their safety and effectiveness.
April 2016 in “Journal of Investigative Dermatology” The Engrailed-1 gene plays a key role in the development of sweat glands in mice.
1 citations
,
February 2024 in “Pharmaceutics” Nanovesicles improve drug delivery through the skin, offering better treatment outcomes and fewer side effects.
6 citations
,
January 2016 in “Springer eBooks” Invasomes effectively deliver drugs through the skin and have potential for improved treatments.
8 citations
,
June 2022 in “International Journal of Molecular Sciences” Tiny particles called extracellular vesicles show promise for skin improvement and anti-aging in facial care but face challenges like low production and lack of research.
December 2025 in “Pharmaceutics” EV-based drug delivery shows promise but faces challenges in standardization and scalability.
16 citations
,
April 2000 in “Journal of Investigative Dermatology” The AVET system effectively delivers genes to human keratinocytes and may help treat skin diseases.
7 citations
,
June 2022 in “Frontiers in Medicine” ADSC-derived extracellular vesicles show promise for skin and hair regeneration and wound healing.
May 2024 in “International journal of nanomedicine” Plant-derived extracellular vesicles show promise for treating diseases like cancer and inflammation.
40 citations
,
June 2013 in “Molecular Pharmaceutics” The gelatin/β-TCP scaffold with nanoparticles improves wound healing and skin regeneration.